Avaleht › Atoopiline dermatiit (ekseem) › Alabama
Atoopiline dermatiit (ekseem) kliinilised uuringud osariigis Alabama
9 uuringut haiguse Atoopiline dermatiit (ekseem) jaoks otsivad osalejaid osariigis Alabama.
Linnad osariigis Alabama
Ametlik uuringutekst (inglise keeles)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Cahaba Dermatology & Skin Health Center- Site Number : 8400006, Birmingham
- River Region Dermatology and Laser- Site Number : 8400041, Montgomery
VärbamineVaatlusuuring
Vanused 12 ja vanemad · Kõik sood · Uuendatud 29. sept 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Birmingham
- Novartis Investigative Site, Birmingham
VärbamineFaas 2
Vanused 18–100 · Kõik sood · Uuendatud 28. sept 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Birmingham
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 25. sept 2026 · NCT07298395First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Cahaba Dermatology & Skin Health Center, LLC, Birmingham
VärbamineFaas 1Terved vabatahtlikud oodatud
Vanused 18–65 · Kõik sood · Uuendatud 25. sept 2026 · NCT07527923A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Cahaba Dermatology & Skin Health Center, Birmingham
VärbamineFaas 3
Vanused 2–11 · Kõik sood · Uuendatud 25. sept 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- AllerVie Clinical Research, Birmingham
- Cahaba Dermatology and Skin Health Center, Birmingham
VärbamineFaas 2
Vanused 18–65 · Kõik sood · Uuendatud 28. aug 2026 · NCT07599813A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Birmingham
VärbamineFaas 3
6 Months – 11 Years · Kõik sood · Uuendatud 7. juuli 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Cahaba Dermatology & Skin Health Center /ID# 263855, Birmingham
VärbamineFaas 3
Vanused 18–63 · Kõik sood · Uuendatud 6. juuli 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Allervie Clinical Research, Birmingham
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 4. mai 2026 · NCT05995964Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.